IGNITE
Cambridge Biomedical Campus

IGNITE

IGNITE is the innovation and experimental-medicine programme of the Cheriyan Group, bringing together artificial intelligence, digital biomarkers, emerging technologies and novel trial methodologies to transform how cardiovascular disease is studied, detected, monitored and treated.

Innovative Group for Novel Interventions, Trials & Experimental Medicine

About IGNITE

Our work spans AI-enabled and digital biomarkers, adaptive and decentralised clinical trials, intelligent trial design, and precision therapeutics — translating emerging technologies into rigorous clinical research and experimental medicine.

Working in partnership with academia, the NHS and industry, and drawing on Cambridge’s world-leading ecosystem in AI, biomedical science and drug development, IGNITE develops and evaluates next-generation approaches to clinical trials, disease detection and monitoring, and therapeutic development.

Research pillars

Four pillars, one mission

IGNITE integrates artificial intelligence, digital biomarkers, next-generation trial methods and cardiovascular therapeutics into a single translational programme.

Pillar 01

AI & Computational Medicine

  • Machine learning
  • Foundation models
  • Digital twins
  • Clinical decision support
Pillar 02

Digital Biomarkers

  • Voice biomarkers
  • Respiratory acoustics
  • Facial video biomarkers
  • Wearables
  • Passive sensing
  • Remote monitoring
Pillar 03

Innovative Clinical Trials

  • Early-phase studies
  • Adaptive platform trials
  • Decentralised and hybrid trials
  • Bayesian methods
  • Digital endpoints
Pillar 04

Cardiovascular Therapeutics

  • Heart failure
  • Hypertension
  • Lipids
  • Inflammation
  • Prevention
  • Cardiometabolic disease
Ecosystem

Why Cambridge?

Cambridge offers one of the world’s most concentrated environments for healthcare innovation. IGNITE leverages this unique ecosystem by bringing together:

  • University of Cambridge
    Internationally recognised expertise in AI, engineering, data science and biomedical research.
  • Cambridge University Hospitals NHS Foundation Trust
    A leading centre for cardiovascular care, translational research and early-phase clinical trials.
  • Cambridge Biomedical Campus
    One of Europe’s largest life sciences campuses, co-locating academia, the NHS, global pharmaceutical companies and biotechnology innovators.
  • Industry partnerships
    Collaborations spanning pharmaceutical development, digital health, medical devices and AI, enabling rapid evaluation and translation of emerging technologies into clinical practice.
Studies

IGNITE leads and contributes to studies applying AI, wearable sensors and digital biomarkers to the early detection and management of cardiovascular disease.

Completed
Completed
Partner with IGNITE

Collaborations with academia, the NHS and industry

IGNITE welcomes conversations with academic groups, pharmaceutical and biotech partners, and clinicians developing next-generation cardiovascular therapies, digital biomarkers or AI-enabled trial methodologies.